Glaxosmithkline Pharmaceuticals has reported results for fourth quarter and year ended March 31, 2022.
The company has reported many fold jump in its net profit at Rs 1217.84 crore for the quarter under review as compared to Rs 12.75 crore for the same quarter in the previous year. Total income of the company increased by 5.64% at Rs 810.86 crore for Q4FY22 as compared Rs 767.56 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported many fold jump in its net profit at Rs 1219.05 crore for the quarter under review as compared to Rs 14.33 crore for the same quarter in the previous year. Total income of the company increased by 7.02% at Rs 828.39 crore for Q4FY22 as compared Rs 774.03 crore for the corresponding quarter previous year.
For the year ended March 31, 2022, the company has reported above 4-fold jump in its net profit at Rs 1690.53 crore as compared to Rs 357.57 crore for the previous year. Total income of the company increased by 8.68% at Rs 3293.73 crore for year under review as compared to Rs 3030.66 crore for year ended March 31, 2021.
For the year ended March 31, 2022, on the consolidated basis, the company has reported above 4-fold jump at Rs 1694.72 crore as compared to Rs 358.15 crore for the previous year. Total income of the company increased by 10.46% at Rs 3353.81 crore for year under review as compared to Rs 3036.18 crore for year ended March 31, 2021.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1464.85 |
Dr. Reddys Lab | 5955.65 |
Cipla | 1477.15 |
Zydus Lifesciences | 1050.35 |
Lupin | 1603.55 |
View more.. |